Cancer News and Research

Latest Cancer News and Research

Omni Hotels & Resorts partners with GHA to host "Lasso for Life" event

Top marketing representatives of Omni Hotels & Resorts and the other Global Hotel Alliance brand members recently hosted a unique "Lasso for Life" event benefitting the Leukemia & Lymphoma Society (LLS).

30 Dec 2009

Advances in development of “lipidoid” formulations for systemic delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators from the David H. Koch Institute for Integrative Research at the Massachusetts Institute of Technology (MIT) today announced the publication of new data in the journal Proceedings of the National Academy of Sciences (PNAS) describing further advancements in discovery and development of novel “lipidoid” formulations for the systemic delivery of RNAi therapeutics.

30 Dec 2009

Acupuncture also improves sex drive while reducing hot flashes in breast cancer patients

Not only is acupuncture as effective as drug therapy at reducing hot flashes in breast cancer patients, it has the added benefit of potentially increasing a woman's sex drive and improving her sense of well-being, according to a Henry Ford Hospital study.

30 Dec 2009

TRAP-1 may prevent cancer cell death, current research suggests

Current research suggests that TNF-receptor associated protein-1 (TRAP-1) may prevent cancer cell death. The related report by Leav et al, "Cytoprotective Mitochondrial Chaperone TRAP-1 as a Novel Molecular Target in Localized and Metastatic Prostate Cancer," appears in the January 2010 issue of the American Journal of Pathology.

30 Dec 2009

Phase 3 trial of figitumumab discontinued by Pfizer

Pfizer Inc. announced today the discontinuation of A4021016 (also known as ADVIGO 1016), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) as first-line treatment in patients with advanced non-adenocarcinoma non-small cell lung cancer (NSCLC) due to the study meeting predefined boundaries for early termination.

30 Dec 2009

Luna Innovations acquires intellectual property assets of Tego Biosciences

Luna Innovations Incorporated has acquired certain intellectual property assets of Tego Biosciences, its main competitor in developing medicines based on carbon nanomaterials.

29 Dec 2009

Results from Bionovo's study on BN107 published

Bionovo, Inc. announced today the publication of results from its study on the anti-tumor mechanism of BN107. The results of the study, published in the International Journal of Cancer, describe the potential molecular mechanisms mediating the selective pro-apoptotic (cell death) effect induced by BN107 on estrogen receptor negative (ER-) breast cancer cells.

29 Dec 2009

Affomix to generate antibodies against proprietary targets chosen by Kalgene

Affomix Corporation, a pioneer in the development of automated, high-throughput monoclonal antibody selection technology, announced today that Kalgene Pharmaceuticals Inc. has signed a commercial agreement to have Affomix utilize its Y2HExpress™ technology to select antibodies with potential diagnostic and therapeutic utility in breast cancer. Kalgene Pharmaceuticals Inc. is a private company focused on the development of oncology therapeutics and companion diagnostics.

29 Dec 2009

DMET genotyping platform screens for 1256 genetic variations in 170 genes

It's the ultimate goal in the treatment of cancer: tailoring a person's therapy based on his or her genetic makeup. While a lofty goal, scientists are steadily moving forward, rapidly exploiting new technologies. Researchers at Georgetown Lombardi Comprehensive Cancer Center report a significant advance in this field of research using a new chip that looks for hundreds of mutations in dozen of genes.

29 Dec 2009

AngioDynamics introduces its new Total Abscession nephrostomy drainage catheter

AngioDynamics announced today the release of its new Total Abscession nephrostomy drainage catheter. The launch of this product completes the Total Abscession family of products – including general drains and a biliary drainage catheter – giving physicians and hospitals a full range of choice from one source.

29 Dec 2009

Health gurus say recommit each Monday to resolve the smoking habit

On January 1st millions of Americans will resolve to quit smoking -- again. Yet many will resume their addiction by Groundhog's Day. Now authorities at Johns Hopkins and the American Cancer Society say it doesn't have to be that way. If a quitter falls off the wagon, the pros agree, just quit again the following Monday. And recommit to stay quit each Monday thereafter.

29 Dec 2009

Elekta Crawley receives the World Class Manufacturer of the Year 2009 award

Elekta, the world-leading manufacturer of treatment solutions for cancer and brain disorders, has been awarded the prestigious World Class Manufacturing award by The Manufacturer magazine. The award was given in recognition of the quality work produced each year by Elekta manufacturing staff.

From Elekta 29 Dec 2009

Advaxis reports 3-year survival data from its ADXS11-001 Phase I trial for cervical cancer

The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc., the company that pioneered the live, attenuated Listeria monocytogenes (Lm) vaccine, has shown thirty-six (36) month survival in two (2) of the thirteen (13) evaluable patients treated with Advaxis’ therapeutic cancer vaccine, indicating the possibility of persistent immune protection, from only a two (2) dose initial regimen.

29 Dec 2009

CyberAlert offers free media monitoring service for not-for-profit organizations

Free media monitoring is available to not-for-profit organizations under a PR grants program established by CyberAlert, Inc., the media monitoring service.

29 Dec 2009

TSC proteins regulate Notch activity

Two independent teams of researchers have identified a role for enhanced activation of the signaling protein Notch in tumors characterized by inactivation of either the TSC1 or the TSC2 protein. As indicated by Warren Pear, at the University of Pennsylvania, Philadelphia, in an accompanying commentary, these data provide a rationale for testing whether Notch inhibitors are of benefit to those with TSC-associated tumors.

29 Dec 2009

Successful RNA interference to turn off multiple genes raises hope for new liver disease treatments

Researchers at MIT and Alnylam Pharmaceuticals report this week that they have successfully used RNA interference to turn off multiple genes in the livers of mice, an advance that could lead to new treatments for diseases of the liver and other organs.

29 Dec 2009

BHS implements Greenway Medical Technologies' fully-integrated EHR solution

Greenway Medical Technologies, Inc. today announced the deployment of its fully-integrated electronic health record (EHR), practice management and interoperability solution, PrimeSuite®, into Palm Beach County, Florida's Bethesda Healthcare System (BHS) and its flagship hospital, Bethesda Memorial Hospital. BHS operates the 401-bed hospital as well as specialty practices that include family practice, internal medicine, cardiovascular surgery, neurology and orthopedics.

29 Dec 2009

SU2C opens fully stocked online store to support cancer research

This is where the end of cancer begins… with the start of the New Year. Just in time for the New Year, Stand Up To Cancer (SU2C) is opening a fully stocked online store whose proceeds will support cancer research to bring new therapies to patients faster.

29 Dec 2009

Promising results from Soligenix' RiVax vaccine against ricin toxin

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today the publication of an article in the January 2010 edition of Infection and Immunity, detailing the characteristics of several immunodominant regions of ricin A chain, the antigenic component of RiVax((TM)). RiVax((TM)) is Soligenix's vaccine to protect against exposure to ricin toxin and is currently being evaluated in Phase 1 human safety and immunogenicity trials, as well as nonhuman primate trials for efficacy.

29 Dec 2009